Get started
INTRA-CELLUAR THERINTRA-CELLUAR THERINTRA-CELLUAR THER

INTRA-CELLUAR THER

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals

23I chart


Full chart

23I upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪12.16 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.728 CHF
Net income (FY)
‪−117.60 M‬ CHF
Revenue (FY)
‪390.97 M‬ CHF
Shares float
‪99.30 M‬
Beta (1Y)
0.70

Employees


Employees (FY)
610
Change (1Y)
+49 +8.73%
Revenue / Employee (1Y)
‪640.93 K‬ CHF
Net income / Employee (1Y)
‪−192.78 K‬ CHF

About Intra-Cellular Therapies Inc.


Sector
Health Technology
CEO
Sharon L. Mates
Headquarters
Bedminster
Website
intracellulartherapies.com
Founded
2002
FIGI
BBG00LVDLP83
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

23I news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 23I is 117.646 CHF — it has increased by 90.19% in the past 24 hours. Watch INTRA-CELLUAR THER stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange INTRA-CELLUAR THER stocks are traded under the ticker 23I.
23I stock has risen by 90.19% compared to the previous week, the month change is a 90.19% rise, over the last year INTRA-CELLUAR THER has showed a 101.61% increase.
We've gathered analysts' opinions on INTRA-CELLUAR THER future price: according to them, 23I price has a max estimate of 128.25 CHF and a min estimate of 79.70 CHF. Watch 23I chart and read a more detailed INTRA-CELLUAR THER stock forecast: see what analysts think of INTRA-CELLUAR THER and suggest that you do with its stocks.
23I reached its all-time high on Jan 13, 2025 with the price of 117.677 CHF, and its all-time low was 58.350 CHF and was reached on Jan 24, 2024. View more price dynamics on 23I chart.
See other stocks reaching their highest and lowest prices.
23I stock is 47.45% volatile and has beta coefficient of 0.70. Track INTRA-CELLUAR THER stock price on the chart and check out the list of the most volatile stocks — is INTRA-CELLUAR THER there?
Today INTRA-CELLUAR THER has the market capitalization of ‪12.16 B‬, it has increased by 17.51% over the last week.
Yes, you can track INTRA-CELLUAR THER financials in yearly and quarterly reports right on TradingView.
INTRA-CELLUAR THER is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
23I earnings for the last quarter are −0.21 CHF per share, whereas the estimation was −0.15 CHF resulting in a −39.48% surprise. The estimated earnings for the next quarter are −0.06 CHF per share. See more details about INTRA-CELLUAR THER earnings.
INTRA-CELLUAR THER revenue for the last quarter amounts to ‪148.62 M‬ CHF, despite the estimated figure of ‪146.01 M‬ CHF. In the next quarter, revenue is expected to reach ‪176.30 M‬ CHF.
23I net income for the last quarter is ‪−22.31 M‬ CHF, while the quarter before that showed ‪−14.58 M‬ CHF of net income which accounts for −52.98% change. Track more INTRA-CELLUAR THER financial stats to get the full picture.
No, 23I doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 22, 2025, the company has 610.00 employees. See our rating of the largest employees — is INTRA-CELLUAR THER on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTRA-CELLUAR THER EBITDA is ‪−102.61 M‬ CHF, and current EBITDA margin is −34.21%. See more stats in INTRA-CELLUAR THER financial statements.
Like other stocks, 23I shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTRA-CELLUAR THER stock right from TradingView charts — choose your broker and connect to your account.